
Larimar Therapeutics, Inc. — Investor Relations & Filings
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company utilizes a proprietary intracellular delivery platform to design fusion proteins that deliver therapeutic molecules to targets within cells. Its lead product candidate, nomlabofusp (formerly CTI-1601), is a recombinant fusion protein being evaluated in a Phase 2 clinical program for the treatment of Friedreich's ataxia, a rare and progressive genetic disease. Larimar Therapeutics plans to leverage its platform to develop additional therapies for other rare diseases characterized by deficiencies in intracellular proteins.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K | 2026-05-19 | English | |
| 10-Q | 2026-05-14 | English | |
| 8-K | 2026-05-14 | English | |
| S-8 - Larimar Therapeutics, Inc. (0001374690) (Filer) | 2026-03-19 | English | |
| 10-K - Larimar Therapeutics, Inc. (0001374690) (Filer) | 2026-03-19 | English | |
| 8-K - Larimar Therapeutics, Inc. (0001374690) (Filer) | 2026-03-19 | English |
Browse filings by year
18 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 46557399 | 8-K | 2026-05-19 | English | ||
| 46282456 | 10-Q | 2026-05-14 | English | ||
| 45966119 | 8-K | 2026-05-14 | English | ||
| 32989784 | S-8 - Larimar Therapeutics, Inc. (0001374690) (Filer) | 2026-03-19 | English | ||
| 32989111 | 10-K - Larimar Therapeutics, Inc. (0001374690) (Filer) | 2026-03-19 | English | ||
| 32985493 | 8-K - Larimar Therapeutics, Inc. (0001374690) (Filer) | 2026-03-19 | English | ||
| 32890859 | 4 - LARIMAR THERAPEUTICS, INC. (0001374690) (Filer) | 2026-03-03 | English | ||
| 32890855 | 4 - LARIMAR THERAPEUTICS, INC. (0001374690) (Filer) | 2026-03-02 | English | ||
| 32890857 | 4 - LARIMAR THERAPEUTICS, INC. (0001374690) (Filer) | 2026-03-02 | English | ||
| 32890858 | 4 - LARIMAR THERAPEUTICS, INC. (0001374690) (Filer) | 2026-03-02 | English | ||
| 32890863 | 8-K - LARIMAR THERAPEUTICS, INC. (0001374690) (Filer) | 2026-02-26 | English | ||
| 32890866 | 8-K - LARIMAR THERAPEUTICS, INC. (0001374690) (Filer) | 2026-02-24 | English | ||
| 29193640 | SCHEDULE 13G/A Filing | 2026-02-12 | English | ||
| 29193648 | 4 Filing | 2026-01-27 | English | ||
| 29193643 | 4 Filing | 2026-01-27 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Annovis Bio, Inc.
A clinical-stage drug platform company developing therapies…
|
ANVS | US | Professional, scientific and te… |
|
AnorMED Inc.
Developed small molecule therapeutics for serious diseases,…
|
— | CA | Professional, scientific and te… |
|
ANTEOTECH LTD
Develops nanoglue technology for life sciences and lithium-…
|
ADO | AU | Professional, scientific and te… |
|
Anthem Biosciences Limited
Integrated CRAMS organization for drug discovery, developme…
|
ANTHEM | IN | Professional, scientific and te… |
|
APPLIED DNA SCIENCES INC
Develops and manufactures DNA-based technologies for geneti…
|
APDN | US | Professional, scientific and te… |
|
Aprea Therapeutics, Inc.
Clinical-stage biopharma developing cancer therapeutics via…
|
APRE | US | Professional, scientific and te… |
|
AprilBio Co.,Ltd.
Develops long-acting biologic drugs for autoimmune diseases…
|
397030 | KR | Professional, scientific and te… |
|
Aptahem AB
A clinical-stage biotech developing aptamer-based drugs for…
|
APTA | SE | Professional, scientific and te… |
|
APTAMER GROUP PLC
Develops custom affinity binders for research, diagnostics,…
|
APTA | GB | Professional, scientific and te… |
|
Aptevo Therapeutics Inc.
Clinical-stage biotech developing antibody-based immunother…
|
APVO | US | Professional, scientific and te… |
Larimar Therapeutics, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/33359/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=33359 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=33359 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=33359 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 33359}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Larimar Therapeutics, Inc. (id: 33359)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.